Press Releases for LLY

Press Releases
China's Returnee Entrepreneurship: In the Right Place at the Right Time
Analyst Choice Initiates Market Analysis on Healthcare, Technology and Consumer Goods Sectors
ConocoPhillips up 21% Since Added to Galtstock Long-Term Portfolio
Phase Forward Reports Third Quarter 2009 Results
Eli Lilly to pay S. Carolina $45 million
Bristol-Myers Squibb Achieves Strong Sales, Earnings Performance in Third Quarter
Licensing Executives Society Announces 2009 Deals of Distinction Awards
Drug makers, CVS slammed for promos
Eli Lilly to sell plant, saving 700 jobs
Indianapolis Prize 2010 nominees announced
Best Practices to Speed-Up Pharmaceutical Analysis Processes From Johnson & Johnson, Pfizer, Genentech and Eli Lilly at Pharma IQ's Forum on Laboratory Informatics
PHT Corporation Promotes Dwight Cooper to Vice President of Client Services
Teva Provides Update on Generic Evista® Litigation
Most see heart attack as wake-up call
Deltagen Reports 2009 Second Quarter Financial Results
Transition Therapeutics Announces Fiscal 2009 Year End Financial Results
Osteoporosis drug may slow cartilage loss
Symyx Joins SAFE-BioPharma to Ensure Safe Security Standards for ELN Software; Pharmaceutical Industry Non-Profit Maintains Standards and Certification for Digital Signatures
Eli Lilly to reduce workforce
Eli Lilly to lay off 5,500
UPI NewsTrack Business
Eli Lilly to lay off 35,000
Fitch: Credit Quality Stable for Global Pharma Sector With Increase of New Drug Approvals in 2Q'09
ONE Holdings' Subsidiary Green Planet Launches Two New Health Extracts
Repligen Elects Glenn L. Cooper, M.D. To the Board of Directors
Grammy(R)-Nominated R&B Sensation Angie Stone Teams up With the American Diabetes Association to Encourage African-Americans to be Victorious in the Face of Diabetes
Lilly moves on from Prozac to Cymbalta
Lilly pulls plug on osteoporosis drug
Lilly Reports on Outcome of Phase III Study of Arzoxifene
Spencer Trask Ventures Inc. Leads $7-Million InnoCentive Financing
U.S. District Court Rules Against Lilly Regarding Gemzar Patent
Galapagos Reports Revenue Growth and Improved Net Result in 1H 2009
Chemaphor and Elanco End Relationship
Effient(TM) is Now Available in Pharmacies
Lilly Broadens Income Eligibility for Patient Assistance Programs
Safeguard Scientifics Announces Second Quarter 2009 Financial Results
Lilly Announces Continued Commitment to Transparency with Faculty Registry
United Therapeutics Corporation Reports Second Quarter 2009 Financial Results
Eli Lilly & Company and ScinoPharm Taiwan Ltd. Announce Settlement of Gemcitabine Litigation
Phase Forward Reports Second Quarter 2009 Results
Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial In Secondary Progressive Multiple Sclerosis
Lilly to Unveil More Than 30 Studies at Premier Lung Cancer Meeting
Lilly Receives Award From National Medical Association
/C O R R E C T I O N -- Eli Lilly and Company/
FDA Approves Expanded Use of Lilly's FORTEO(R) [teriparatide (rDNA origin) injection] to Treat Glucocorticoid-Induced Osteoporosis
Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
InvestorSoup.com Issues Trading Outlook for Johnson & Johnson
Lilly Reports Solid Second-Quarter 2009 Results, Raises EPS Guidance
National Report Ranks Oklahoma as a Top State for Mental Health Services
Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
ImClone Systems and Bristol-Myers Squibb Announce Revisions to ERBITUX® (cetuximab) U.S. Product Labeling for Metastatic Colorectal Cancer
Phase Forward Celebrates Five Years on NASDAQ
FDA gives nod to blood-thinning drug
Daiichi Sankyo and Lilly Receive U.S. FDA Approval for Effient(TM)
ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo
New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
UPI NewsTrack Health and Science News
Lilly Sets Date and Conference Call for Second-Quarter 2009 Financial Results Announcement
FDA OKs first lung cancer maintenance drug
Top 10 Tips for Staying Healthy When Money is Tight
Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
Cellceutix Announces Dr. Emil Frei to Be On Its Scientific Advisory Board Through June 30, 2010
Galapagos Awarded Innovative Enterprise Qualification in France
wRatings and UTEK Corporation's Strategos Identify Most Competitive Health Care Companies
wRatings and UTEK Corporation's Strategos Identify Most Competitive Health Care Companies
Lilly Declares Third-Quarter Dividend
SAFE-BioPharma Changes Fees to Help Clinical Investigators, CROs, Others
June 23 DIA Sessions Chaired By SAFE-BioPharma Association
MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
Eli Lilly and Company Announces New Drug Discovery Initiative
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
Reportlinker Adds R&D Cost Cutting: Managing Cost Containment and Safeguarding Productivity
FDA Advisory Committee Votes in Favor of Zyprexa for Two Adolescent Indications
Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
Reliant Energy Selects Grey As Its Branding and Advertising Agency
Successful Disease Management Programs Can Play Role in Health Care Reform
Aileron Therapeutics Closes $40 Million Series D Financing
Interim Study Results Presented at ADA 2009: Exenatide Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs
Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes
Bart Peterson to Join Lilly Leadership Team
Lilly resubmits Cymbalta application
Springborn Smithers Receives 2009 Lilly Global Supplier Award
Lilly Resubmits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
R. David Hoover Elected to Lilly Board of Directors
ARIAD Announces Updates On NF-ÎºB Patent Appeals
Study Showed Lilly's GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
Alkermes Reports Financial Results for Fiscal 2009 and Provides Financial Expectations for Fiscal 2010
Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results
NextBio Appoints Jim Merryweather Vice President of Business Development
BioMS Medical Announces First Quarter 2009 Results
Phase Forward to Host Seventh Annual European Users Conference
Safeguard Scientifics Announces First Quarter 2009 Financial Results
Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
ThirdAge.Com Selects Interevco to Sell Its Online Advertising
Phase Forward Reports First Quarter 2009 Results
Pacgen to Acquire Xphase Pharmaceuticals